Robert Brenner - 23 Feb 2026 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Reporting relationship: Chief Medical Officer
Issuer ticker: VERA
Reported as of: 23 Feb 2026
Net transaction value: -$90,307
SEC form: 4
Accepted by SEC: 25 Feb 2026, 20:01:07 UTC
Prior SEC filing: 06 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph R. Young, Attorney-in-Fact

Key filing fact

Robert Brenner filed Form 4 for Vera Therapeutics, Inc. (VERA) on 25 Feb 2026.

Key facts

This page summarizes Robert Brenner's Form 4 filing for Vera Therapeutics, Inc. (VERA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 25 Feb 2026, 20:01.

Change

Previous filing in this sequence was filed on 06 Feb 2026.
Current net transaction value: -$90,307.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002006910 Primary reporting owner

Brenner Robert

Relationship: Chief Medical Officer
Address: C/O VERA THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Signature: /s/ Joseph R. Young, Attorney-in-Fact
Signature date: 25 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VERA transaction

Class A Common Stock

Sale

Transaction value: $90,307
Shares: -2,151
Change %: -4.1%
Price: $41.98
Shares after: 50,947
Date: 23 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026.

Footnote F2

Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person.

Footnote F3

The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.